Coherus Oncology (CHRS) Convertible Debt (2016 - 2025)
Coherus Oncology (CHRS) posted Convertible Debt of $228.6 million for Q1 2025, little changed sequentially from $228.2 million in Q4 2024, and up 0.59% YoY from $227.2 million in Q1 2024.
Coherus Oncology (CHRS) Convertible Debt (2016 - 2025) Analysis & Trends
Coherus Oncology has reported Convertible Debt for 10 years, with the latest figure at $228.6 million in Q1 2025.
- Quarterly Convertible Debt rose 0.59% year-over-year to $228.6 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $228.6 million (up 0.59% YoY) and the FY2024 annual result came in at $228.2 million, up 0.59% from the prior year.
- Convertible Debt steadied at $228.6 million in Q1 2025 per CHRS's latest filing, from $228.2 million in the prior quarter.
- Over five years, Convertible Debt peaked at $332.8 million in Q4 2021 and troughed at $223.3 million in Q1 2021.
- A 5-year average of $232.3 million and a median of $226.2 million in 2023 frame the typical range for Convertible Debt.
- The sharpest annual moves came in 2021 and 2022: Convertible Debt jumped 316.56% in 2021, then slumped 32.21% in 2022.
- Over 5 years, Convertible Debt stood at $332.8 million in 2021, then plunged by 32.21% to $225.6 million in 2022, then increased by 0.58% to $226.9 million in 2023, then gained by 0.59% to $228.2 million in 2024, then climbed by 0.15% to $228.6 million in 2025.
- According to Business Quant data, Convertible Debt over the past three periods registered $228.6 million, $228.2 million, and $227.9 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - |
| 10 | Coherus Oncology | 210.55 Mn | 105.25 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 228.57 Mn |
| Dec 31, 2024 | 228.23 Mn |
| Sep 30, 2024 | 227.89 Mn |
| Jun 30, 2024 | 227.56 Mn |
| Mar 31, 2024 | 227.22 Mn |
| Dec 31, 2023 | 226.89 Mn |
| Sep 30, 2023 | 226.56 Mn |
| Jun 30, 2023 | 226.23 Mn |
| Mar 31, 2023 | 225.90 Mn |
| Dec 31, 2022 | 225.58 Mn |
| Sep 30, 2022 | 225.25 Mn |
| Jun 30, 2022 | 224.93 Mn |
| Mar 31, 2022 | 224.61 Mn |
| Dec 31, 2021 | 332.77 Mn |
| Sep 30, 2021 | 223.97 Mn |
| Jun 30, 2021 | 223.66 Mn |
| Mar 31, 2021 | 223.34 Mn |
| Dec 31, 2020 | 79.89 Mn |
| Sep 30, 2020 | 222.72 Mn |
| Jun 30, 2020 | 79.20 Mn |